The integrative approach identified more gene sets related to fibroblast growth factor receptor (FGFR) signaling, which is amplified in many breast cancers [46] and has been linked to lapatinib resistance in HER2-positive breast cancer cells [47]. The gene discussed is ERBB2; the disease is breast cancer.